Finance

Lists
2359:HKG
WuXi AppTec Ord Shs H
၁၉၆.၂၀ HK$
၀.၀၀%
(၀.၀၀) 1D
အောက် ၂၀, GMT+၈ ၁၄:၄၀:၁၅  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 2359...
Open
၁၉၄.၀၀ HK$
High
၂၀၀.၀၀ HK$
Low
၁၉၂.၇၀ HK$
Mkt. cap
ဋေ ၅.၂၅ သ
Avg. vol.
၄.၃၁ သန်း
Volume
၄.၀၂ သန်း
Dividend
၁.၂၂%
Quarterly dividend
၀.၆၀ HK$
Ex-dividend date
၂၀၂၆ စက် ၄
P/E ratio
၂၃.၉၇
52-wk high
၂၁၉.၂၀ HK$
52-wk low
၉၆.၇၀ HK$
EPS
၈.၁၈ HK$
No. of employees
၄ သောင်း
Open
၁၉၄.၀၀ HK$
High
၂၀၀.၀၀ HK$
Low
၁၉၂.၇၀ HK$
Mkt. cap
ဋေ ၅.၂၅ သ
Avg. vol.
၄.၃၁ သန်း
Volume
၄.၀၂ သန်း
Dividend
၁.၂၂%
Quarterly dividend
၀.၆၀ HK$
Ex-dividend date
၂၀၂၆ စက် ၄
P/E ratio
၂၃.၉၇
52-wk high
၂၁၉.၂၀ HK$
52-wk low
၉၆.၇၀ HK$
EPS
၈.၁၈ HK$
No. of employees
၄ သောင်း
News stories
From web sources and news partners
ad-hoc-news.de
ad-hoc-news.de
·
ပြီးခဲ့သည့် ၃၈ မိနစ်
WuXi AppTec stock receives CRDMO award ahead of Xetra open
Yahoo! Finance Canada
Yahoo! Finance Canada
·
ပြီးခဲ့သည့် ၆ နာရီ
Frost & Sullivan awards WuXi AppTec with 2026 Global Company of the Year Recognition for CRDMO Leadership
ad-hoc-news.de
ad-hoc-news.de
·
ပြီးခဲ့သည့် ၁၅ နာရီ
WuXi AppTec stock: October 27 results date is set for WuXi AppTec stock
Profile
WuXi AppTec Co., Ltd. is a Chinese provider of contract research, development, and manufacturing, services for the pharmaceutical and life-sciences industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America, and Europe. Founded in 2000 by chemist Ge Li as WuXi PharmaTech, the company expanded through acquisitions and re‑listings in 2018 after a 2015 take‑private. It produces a large part of the ingredients used in treatments for illnesses including leukemia, lymphoma, HIV, and obesity. As of 2025, the company reported around 39,000 employees and 6,000 customers. Its clients have included Jiangsu Hengrui, GlaxoSmithKline, AstraZeneca and Pfizer. Wikipedia
About WuXi AppTec Ord Shs H
CEOSteve Yang | Ge Li
Employees၃.၅၆ သောင်း
Founded၂၀၀၀ ဒီ ၁
Headquarters-
Sector-
Last report
၂၀၂၆ ဩ ၃
Fiscal period
Q2 2026
၂.၂၀ CN¥ / ၁.၃၄ CN¥
+၆၄.၁၈%beat
Revenue / Est. (CNY)
ဋေ ၁.၆၅ ထ / ဋေ ၁.၂၉ ထ
+၂၈.၀၃%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
ဋေ ၁.၂၀ ထ
ဋေ ၁.၁၀ ထ
ဋေ ၁.၂၄ ထ
ဋေ ၁.၆၅ ထ
Cost of goods sold
၆၀၆.၉၅ ဋေ
၄၉၀.၅၄ ဋေ
၆၁၆.၇၈ ဋေ
-
Cost of revenue
၆၀၆.၉၅ ဋေ
၄၉၀.၅၄ ဋေ
၆၁၆.၇၈ ဋေ
-
Research and development expenses
၃၁.၁၇ ကုဋေ
၂၃.၆၉ ကုဋေ
၂၆.၇၀ ကုဋေ
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၈၅.၄၅ ကုဋေ
၈၅.၃၇ ကုဋေ
၈၉.၁၈ ကုဋေ
-
Operating expense
၁၃၈.၁၇ ဋေ
၁၂၆.၄၄ ဋေ
၁၂၂.၃၄ ဋေ
-
Total operating expenses
၇၄၅.၁၂ ဋေ
၆၁၆.၉၈ ဋေ
၇၃၉.၁၂ ဋေ
-
Operating income
၄၅၉.၃၈ ဋေ
၄၈၀.၁၀ ဋေ
၅၀၄.၄၅ ဋေ
-
Other non operating income
-၄၇.၀၄ ကုဋေ
၂၈.၁၄ ကုဋေ
-၂၆.၆၄ ကုဋေ
-
EBT including unusual items
၅၁၃.၀၉ ဋေ
၆၇၅.၂၀ ဋေ
၅၆၀.၇၃ ဋေ
-
EBT excluding unusual items
၅၁၀.၅၁ ဋေ
၆၉၅.၀၄ ဋေ
၅၁၈.၇၀ ဋေ
-
Income tax expense
၁၅၄.၈၈ ဋေ
၁၀၈.၈၄ ဋေ
၉၃.၆၈ ကုဋေ
-
Effective tax rate
၃၀.၁၉%
၁၆.၁၂%
၁၆.၇၁%
-
Other operating expenses
၅.၈၀ ကုဋေ
၂.၅၈ ကုဋေ
၇.၂၆ သိန်း
-
Net income
၃၅၁.၄၆ ဋေ
၇၀၇.၅၁ ဋေ
၄၆၅.၁၅ ဋေ
-
Net profit margin
၂၉.၁၈%
၆၄.၄၉%
၃၇.၄၀%
-
Earnings per share
၁.၂၄
၁.၄၂
၁.၅၇
၂.၂၀
Interest and investment income
၁၂၀.၈၄ ဋေ
၁၈၆.၈၁ ဋေ
၄၃.၉၈ ကုဋေ
-
Interest expense
-၂၂.၆၇ ကုဋေ
-
-၃.၁၀ ကုဋေ
-
Net interest expenses
၉၈.၁၇ ကုဋေ
၁၈၆.၈၁ ဋေ
၄၀.၈၉ ကုဋေ
-
Depreciation and amortization charges
-
-
-
-
EBITDA
၅၂၀.၈၁ ဋေ
၅၆၀.၅၃ ဋေ
၅၈၄.၈၉ ဋေ
-
Gain or loss from assets sale
-၁၅.၈၀ ကုဋေ
၂၁.၈၄ ကုဋေ
-
-
AI content may include mistakes. Learn more
Google အက်ပ်များ